Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 2Recurrent Uterine Corpus Sarcoma 1Endometrial Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Bilateral Breast Carcinoma 1

Interventions

Taxes 3Paclitaxel 3Carboplatin 3Immunoglobulin G 2Disulfides 2Bevacizumab 2trastuzumab biosimilar HLX02 1temsirolimus 1nintedanib 1linrodostat 1ixabepilone 1cediranib 1brivanib 1Trastuzumab 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Gemcitabine 1Epothilones 1Cisplatin 1Brachytherapy 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Adenocarcinoma × Epothilones × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡